share_log

The Five-year Loss for China Traditional Chinese Medicine Holdings (HKG:570) Shareholders Likely Driven by Its Shrinking Earnings

The Five-year Loss for China Traditional Chinese Medicine Holdings (HKG:570) Shareholders Likely Driven by Its Shrinking Earnings

中国中药控股(HKG: 570)股东的五年亏损可能是其收益萎缩所致
Simply Wall St ·  01/30 00:20

For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long term China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) shareholders for doubting their decision to hold, with the stock down 42% over a half decade. Even worse, it's down 21% in about a month, which isn't fun at all.

对于许多人来说,投资的要点是产生比整个市场更高的回报。但是在任何投资组合中,个股之间的结果都会好坏参半。因此,从长远来看,我们不会责怪中国中药控股有限公司Limited(HKG: 570)股东对他们的持股决定表示怀疑,该股在五年内下跌了42%。更糟糕的是,它在大约一个月内下降了21%,这一点都不好玩。

While the stock has risen 8.0% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

尽管该股在过去一周上涨了8.0%,但长期股东仍处于亏损状态,但让我们看看基本面能告诉我们什么。

See our latest analysis for China Traditional Chinese Medicine Holdings

查看我们对中国中药控股的最新分析

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

虽然市场是一种强大的定价机制,但股价反映了投资者的情绪,而不仅仅是潜在的业务表现。考虑市场对公司的看法发生了怎样的变化的一种不完美但简单的方法是将每股收益(EPS)的变化与股价走势进行比较。

Looking back five years, both China Traditional Chinese Medicine Holdings' share price and EPS declined; the latter at a rate of 8.9% per year. This change in EPS is reasonably close to the 10% average annual decrease in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. So it's fair to say the share price has been responding to changes in EPS.

回顾五年,中国中药控股的股价和每股收益均有所下降;后者每年下降8.9%。每股收益的变化相当接近股价平均年下降10%。这表明,在那段时间内,公司周围的市场情绪没有太大变化。因此,可以公平地说,股价一直在应对每股收益的变化。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下图描述了 EPS 随着时间的推移是如何变化的(点击图片可以看到确切的值)。

earnings-per-share-growth
SEHK:570 Earnings Per Share Growth January 30th 2024
SEHK: 570 每股收益增长 2024 年 1 月 30 日

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of China Traditional Chinese Medicine Holdings' earnings, revenue and cash flow.

我们很高兴地向大家报告,首席执行官的薪酬比资本相似公司的大多数首席执行官要低得多。但是,尽管首席执行官的薪酬总是值得检查的,但真正重要的问题是公司未来能否增加收益。查看这张中国中药控股收益、收入和现金流的互动图表,深入了解收益。

What About Dividends?

分红呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of China Traditional Chinese Medicine Holdings, it has a TSR of -37% for the last 5 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence!

重要的是要考虑任何给定股票的股东总回报率和股价回报率。股东总回报率是一种回报计算方法,它考虑了现金分红的价值(假设收到的任何股息都经过再投资)以及任何贴现资本筹集和分拆的计算价值。可以公平地说,股东总回报率为支付股息的股票提供了更完整的画面。就中国中药控股而言,其过去5年的股东回报率为-37%。这超过了我们之前提到的其股价回报率。而且,猜测股息支付在很大程度上解释了这种分歧是没有好处的!

A Different Perspective

不同的视角

China Traditional Chinese Medicine Holdings shareholders are down 18% over twelve months (even including dividends), which isn't far from the market return of -17%. So last year was actually even worse than the last five years, which cost shareholders 6% per year. It will probably take a substantial improvement in the fundamental performance for the company to reverse this trend. It's always interesting to track share price performance over the longer term. But to understand China Traditional Chinese Medicine Holdings better, we need to consider many other factors. Even so, be aware that China Traditional Chinese Medicine Holdings is showing 1 warning sign in our investment analysis , you should know about...

中国中药控股股东在十二个月内下跌了18%(甚至包括股息),与-17%的市场回报率相差不远。因此,去年的情况实际上比过去五年还要糟糕,后者每年使股东损失6%。要扭转这一趋势,该公司的基本业绩可能需要大幅改善。长期跟踪股价表现总是很有意思的。但是,要更好地了解中国中药控股,我们需要考虑许多其他因素。即便如此,请注意,中国中药控股在我们的投资分析中显示了1个警告信号,您应该知道...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,请看一下我们预计收益将增加的这份免费公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发